ScreenerHero

0HS8Caladrius Biosciences, Inc.

LSE · GB · Healthcare · Biotechnology · lisata.com
1.350USD+19.47%Mkt Cap: —P/E: —

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational prod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap—
Enterprise Value2.37M $
Revenue (TTM)100.00K $
Gross Profit100.00K $
Net Income (TTM)-14.62M $
Revenue/Share0.0110 USD
Last Price1.350 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.14
EV/Revenue23.69
P/S—
P/B1.60
EPS (TTM)-0.39
EPS (Forward)—
52W Range
1.07056% of range1.570
52W High1.570 USD
52W Low1.070 USD
Profitability
Gross Margin100.00%
Oper. Margin-16426.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-101.66%
ROA-56.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.32M $
CapEx (TTM)—
FCF Margin-8100.25%
FCF Yield—
Net Debt-10.44M $
Net Debt/EBITDA0.64
Balance Sheet
Debt/Equity—
Current Ratio3.69
Quick Ratio3.56
Book Value/Sh0.9040 USD
Cash/Share1.159 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.066667:1
Split DateSep 15, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.11M
Insiders21.11%
Institutions12.03%
Technical
SMA 502.587 (-47.8%)
SMA 2002.902 (-53.5%)
Beta0.88
S&P 52W Chg19.18%
Avg Vol (30d)11.55K
Avg Vol (10d)402
Technical Indicators
RSI (14)26.9
MACD-0.3963
MACD Signal-0.1375
MACD Hist.-0.2588
BB Upper4.875 USD
BB Middle3.164 USD
BB Lower1.453 USD
BB Width108.16%
ATR (14)0.3540 USD
Vol Ratio (20d)45.90x